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Related impuritiesAbstract A selective RP-HPLC method for separation and determination of potential related
impurities (starting materials and by-products of synthesis, and degradants) of dabigatran etexilate
(DAB) drug substance has been developed and validated. The separation was accomplished on a
Inertsil ODS 3V (250 mm  4.6 mm, 5 lm) column connected to a photodiode array (PDA) detector
using 20 mM ammonium formate with 0.1% of triethylamine (pH: 5.0 adjusted with formic acid) as
mobile phase-A and acetonitrile as mobile phase-B, under gradient elution. Two unknown impuri-
ties found in dabigatran etexilate industrial batch stability condition at levels more than 0.1% in
HPLC analysis were characterized preliminarily by ESI-MS/MS studies. The major unknown
(unknown-1) was enriched and isolated by preparative LC and structure was evidenced by 1H
and 13C NMR spectroscopy, mass spectrometry and FT-IR. Another unknown (unknown-2) found
as secondary degradant and structure was proposed by ESI-MS/MS study. This method can be used
for the quality control of both drug substance and drug product. The performance of the method
was validated according to the ICH guide lines for specificity, limit of detection, limit of quantifi-
cation, linearity, accuracy, precision, ruggedness and robustness.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Dabigatran etexilate is a potent, non peptidic small molecule
that specifically and reversibly inhibits both free and clot-
bound thrombin (Eriksson et al., 2005; Wienen et al., 2007;
Van Ryn et al., 2007). It has been approved for the prevention
of stroke and systemic embolism in patients with non-valvular
atrial fibrillation by US Food and Drug Administration in
October 2010 and by European Medicines Agency (EMA) in
August 2011. EMA also approved it in 2008 for prophylaxis
of thromboembolism in patients undergoing total knee orulk drug
Figure 1 Potential associated impurities at different stages of DAB synthesis.
2 J. Nagadeep et al.hip replacement (EMEA, 2008). Dabigatran etexilate mesylate
capsule is marketed under the trade name Pradaxa in the
United States, Australia and European countries. Dabigatran
etexilate (DAB) is chemically designated as (ethyl N-{[2-({[4-
((E)-amino{[hexyloxy)carbonyl]imino} methyl)phenyl]amino}Please cite this article in press as: Nagadeep, J. et al., Gradient RP-HPLC method f
and capsule formulations. Arabian Journal of Chemistry (2015), http://dx.doi.org/1methyl)-1-methyl-1H-benzimidazol-5-yl]carbonyl}-N-pyridin-
2-yl-b-alaninate. It has an empirical formula of C34H41N7O5,
and a molecular weight of 627.73 g mole1.
Currently available oral vitamin K antagonists such
as warfarin have unpredictable pharmacokinetics and showor the determination of potential impurities in dabigatran etexilate in bulk drug
0.1016/j.arabjc.2015.09.006
Figure 2 Typical chromatograms of (a) Dabigatran etexilate
spiked with 0.15% of all impurities in final chromatographic
conditions (pH 5.0), (b) bulk drug stability sample containing
unknown impurities, and (c) Pradaxa capsule test sample.
Table 1 System suitability parameters.
S.No Compound RT(min)
(n= 6)a
RRTb
(n= 6)a
USP
resolutionc
(n= 6)a
USP
tailing
(n= 6)a
1 Impurity-1 3.01 0.08 – 1.20
2 Impurity-2 4.80 0.13 5.3 1.11
3 Impurity-3 6.60 0.18 6.2 1.08
4 Impurity-4 7.62 0.21 2.3 1.07
5 Impurity-5 8.51 0.23 2.4 1.16
6 Impurity-6 13.93 0.38 12.8 1.05
7 Impurity-7 20.29 0.56 14.6 1.04
8 Impurity-8 22.57 0.62 4.4 1.02
9 Impurity-9 29.15 0.80 10.7 1.03
10 Impurity-10 32.68 0.90 8.3 1.07
11 Impurity-11 34.01 0.94 3.9 1.07
12 Impurity-12 34.90 0.96 2.6 1.12
13 DAB 36.37 1.00 3.2 1.07
14 Impurity-13 39.62 1.09 3.9 1.08
15 Impurity-14 40.37 1.11 2.5 1.07
16 Impurity-15 43.35 1.19 5.8 1.13
DAB=Dabigatran etexilate.
a Mean ± SD (n= 6).
b Relative retention times (RRT) were calculated against the
retention time (RT) of dabigatran etexilate.
c Resolutions were calculated between two adjacent components.
Gradient RP-HPLC method for the determination of potential impurities 3numerous drug and food interactions (Ansell et al., 2004),
whereas unfractionated and low molecular weight heparins and
fondaparinux require parenteral administration. Oral administra-
tion of dabigatran etexilate produces a predictable pharmacody-
namic and has been clinically developed in various indications
using fixed-dosing without the need for routine coagulation mon-
itoring or dose adjustment. Anticoagulant treatment reduces the
incidence of death and cardio embolic events (Cinteza, 2013).
Since thrombin plays a key role in the formation of fibrin and
is very important for blood coagulation and platelet activation,
it represents a prime target for the development of anticoagulant
agents for the prevention and treatment of thromboembolic
disorders. A recent trial has also shown that dabigatran etexilate
significantly reduces stroke risk with a better safety profile
compared with warfarin in patients with atrial fibrillation
(Connolly et al., 2009). Dabigatran etexilate converted to a major
active metabolite known as dabigatran by non-specific plasma
and liver esterase (Blech et al., 2008).
Several research papers have been reported in the literature
for the determination of DAB (Bernardi et al., 2013a,b; Damle
and Bagwe, 2014; Geetharam et al., 2014; Pani Kumar et al.,
2015; Khan et al., 2014; Reddy and Rao, 2014) and these
papers were limited to the assay of alone DAB from its
degradants and concurrently DAB in human plasma and other
biological stuff, based on UPLC MS/MS (Delavenne et al.,
2012), HPLC and LC/MS/MS (Bernardi et al., 2015;
Nouman et al., 2015; Laizure et al., 2014; Li et al., 2014;
Ha¨rtter et al., 2012). Monitoring and control of by-products
or impurities at each stage of synthesis is required to get a final
pure form of DAB as per predefined specifications. The
reported related substance methods (Dare et al., 2015;
Pantovic´ et al., 2015) were not suitable to monitor stage wise
by-products during the synthesis of DAB and were only
restricted to only for some of related impurities and the details
of unknown degradants formed under the stress conditions
employed were neither discussed nor characterized. Liquid
chromatography combined with multistage mass spectrometry
(LC-MSn) method was available to characterize the degradants
of dabigatran etexilate (Amrani et al., 2015) and was
not suitable for routine monitoring and quantification of
impurities. To the best of our knowledge, a complete validated
HPLC method for the determination of impurities at different
stages of synthesis i.e. raw materials, by-products and degra-
dants of DAB in bulk drug substances is not reported till date.
Further, no monograph on DAB is published in any of the
pharmacopoeia for compendial applications. During the anal-
ysis of laboratory batches from synthetic process development
of DAB, the impurity-1 to impurity-15 (Figs. 1 and 7) were
identified as potential monitoring impurities to ensure the
quality of active pharma ingredient (API) by controlling them
less than 0.1% as per ICH (ICH, Q3A, 2008). In which
impurity-15 was unknown-1 and found along with unknown-
2 in accelerated stability condition (3 months 40 C/75RH) of
industrial batch at about 0.26% and 0.09%. Unknown-2 was
not isolated, being proved as secondary degradant.
The present manuscript describes (i) Development of a RP-
HPLC method for the separation and determination of DAB
potential related impurities i.e. raw materials, by-products
and degradants of mentioned synthetic procedure in
Figs. 1 and 7 (namely Impurities-1, -2, -3, -4, -5, -6, -7, -8,
-9, -10, -11, -12, -13 and -15) and validation as per ICH guide-
lines (ICH, Q1A (R2), 2003; ICH, Q2 (R1), 2005; ICH, Q7,Please cite this article in press as: Nagadeep, J. et al., Gradient RP-HPLC method fo
and capsule formulations. Arabian Journal of Chemistry (2015), http://dx.doi.org/12000) and (ii) Enrichment, isolation and purification of major
unknown-1 (impurity-15) using preparative LC and
characterization by 1H, 13C, ESI-MS studies and FT-IR.
Proposing unknown-2 as secondary degradation impurity
based on forced degradation study and ESI-MS data.
2. Experimental
2.1. Chemicals and reagents
HPLC grade acetonitrile, ammonium formate and formic acid
were obtained from Merck, Darmstadt, Germany. Triethy-
lamine was purchased from J.T.baker, Mallinckrodt Inc.,
Phillipsburg, NJ, USA. Water used for preparing mobile phaser the determination of potential impurities in dabigatran etexilate in bulk drug
0.1016/j.arabjc.2015.09.006
Table 2 Columns, mobile phase composition, mobile phase buffer pH and modes of elution tried during optimization process.
Trial
No.
Column (250  4.6)
mm, 5 lm
Mobile phase composition Elution
mode
Result
1 Inertsil ODS 3V pH 5.0, 20 mM ammonium formate with 0.1% of
triethylamine:ACN (60:40) (v/v)
Isocratic Out of 15 impurities six impurities were
merged
2 Inertsil ODS 3V pH 5.0, 20 mM ammonium formate with 0.1% of
triethylamine:MeOH (60:40) (v/v)
Isocratic Out of 15 impurities six impurities were
merged
3 Inertsil ODS 3V pH 5.5, 20 mM ammonium formate with 0.1% of
triethylamine:ACN
Gradient Impurities 13 and 14 were merged
4 Inertsil ODS 3V pH 4.5, 20 mM ammonium formate with 0.1% of
triethylamine:ACN
Gradient Impurities 11 and 12 were merged
5 Inertsil C8 pH 5.0, 20 mM ammonium formate with 0.1% of
triethylamine:ACN
Gradient Impurities 11 and 12 were merged
6 Ace-C18 pH 5.0, 20 mM ammonium formate with 0.1% of
triethylamine:ACN
Gradient Impurities 11 and 12, and impurities 14 and
15 were closely eluted
7 Zorbax XDB-C18 pH 5.0, 20 mM ammonium formate with 0.1% of
triethylamine:ACN
Gradient Impurities 4 and 5, and impurities 13 and 14
were merged
8 Zorbax XDB-C8 pH 5.0, 20 mM ammonium formate with 0.1% of
triethylamine:ACN
Gradient Impurities 10 and 11 were merged
Table 3 Comparative 1H and 13C NMR spectral data for DAB and unknown-1 impurity.
Position Dabigatran etexilate mesylate Unknown-1 (Impurity-15)
dC (ppm) 1H dH ppm/Hz dC (ppm) 1H dH ppm/Hz
1 13.75 3H 0.84–0.89/t, 6.0 13.95 3H 0.87–0.91/t, 6.0
2 21.87 2H 1.25–1.36/m 22.49 2H 1.30–1.40/m
3 30.18 2H 1.25–1.36/m 30.21 2H 1.30–1.40/m
4 24.68 2H 1.25–1.36/m 25.42 2H 1.30–1.40/m
5 27.82 2H 1.64–1.69/m 28.63 2H 1.64–1.73/m
6 66.95 2H 3.92–3.99/t, 60 66.20 2H 4.19–4.23/t, 6.0
7 155.74 – – 151.03 – –
8 163.33 – – 170.52 – –
9 123.35 – – 124.15 – –
10, 100 121.94 2H 7.41–7.64/m 129.80 2H 7.65–7.68/m
11, 110 111.72 2H 6.84–6.91/m 111.98 2H 6.68–6.73/m
12 153.24 – – 152.46 – –
13 44.29 2H 4.69/br 44.76 2H 4.55/br
14 153.31 – – 151.60 – –
15 131.38 – – 130.80 – –
16 110.04 1H 7.09–7.17/m 109.07 1H 6.97–7.0/m
17 121.30 1H 7.41–7.64/m 122.34 1H 7.14–7.54/m
18 131.38 – – – –
19 112.39 1H 7.41–7.64/m 119.81 1H 7.30–7.37/m
20 137.90 – – 137.45 – –
21 169.86 – – 170.73 – –
22 153.96 – – 156.02 – –
23 118.50 1H 7.41–7.64/m 121.16 1H 7.65–7.68/m
24 121.30 1H 7.41–7.64/m 137.45 1H 7.30–7.37/m
25 118.50 1H 7.09–7.17/m 121.67 1H 6.68–6.73/m
26 148.62 1H 8.36–8.38/m 148.98 1H 8.41–8.43/m
27 39.66 2H 4.18–4.27/t, 7.5 40.43 2H 4.39–4.44/t, 7.5
28 32.92 2H 2.64–2.69/t, 7.5 33.31 2H 2.77–2.82/t, 7.5
29 170.88 – 171.59 – –
30 59.90 2H 4.18–4.27/q, 7.0 60.50 2H 4.03–4.10/q,7.0
31 13.86 3H 1.08–1.13/t, 7.5 14.12 3H 1.18–1.23/t,7.5
32 30.69 3H 3.77/s 31.40 3H 3.75/s
33 – 3H 2.28/s – – –
NH, NH2 – 3H 10.05, 10.65, 11.80/br NH 8.03, 5.58/br
OH – 1H 6.84–6.91/m
Refer to Fig. 7 for numbering. s, singlet; d, doublet; t, triplet; m, multiplet; br-broad.
4 J. Nagadeep et al.
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DAB and process related substances were gift samples from
a local manufacturing company in Chennai, India.2.2. Apparatus and conditions
HPLC: The system used for method development, forced
degradation and validation study was Agilent HPLC 1200 ser-
ies (Agilent Technologies, Deutschland GmbH, Waldbronn,
Germany) with Ezchrom elite software equipped with
G1322A degasser, G1311A quaternary pump, G1315C auto
injector, G16A column oven and G1315C DAD detector.
The HPLC columns used in this study were as follows:
Inertsil ODS 3V, 250 mm  4.6 mm, 5 lm (GL Sciences,
Japan).
Inertsil C8, 250 mm  4.6 mm, 5 lm (GL Sciences, Japan).
ACE C18, 250 mm  4.6 mm, 5 lm (Advanced Chromatog-
raphy, Scotland).
Zorbax XDB-C18, 250 mm  4.6 mm, 5 lm (Agilent tech-
nologies Inc., USA).
Zorbax XDB-C8, 250 mm  4.6 mm, 5 lm (Agilent tech-
nologies Inc., USA).2.3. Chromatographic conditions
The stationary phase used was Inertsil ODS-3V,
250 mm  4.6 mm, 5 lm particles (GL Sciences Inc., Japan).
The mobile phase-A contains 20 mM of ammonium formate
with 0.1% of triethylamine (pH: 5.0 adjusted with formic acid)
and mobile phase-B contains acetonitrile. The flow rate
was 1.0 mL min1. The developed gradient program was
0.01 min – 30% B, 5.0 min – 30% B, 15.0 min – 35% B,
30.0 min – 45% B, 45.0 min – 55% B, 54.0 min – 65.0% B,
55.0 min – 30.0% B and 60.0 min – 30.0% B. The detection
was performed at 255 nm using a DAD detector. The injection
volume was 10 lL. The column temperature was 30 C.
2.4. LC-MS conditions
The LC-ESI/MS studies were carried out on Q-TOF (Agilent,
USA) 4100 Quadrupole mass spectrometer, ion source voltage
5500 V, de clustering potential 40 V, entrance potential 10 V,
with the nebulizer gas as nitrogen at 40 psi. The LC part con-
sisted of Agilent 1260 series HPLC system with binary gradient
pump with a degasser and an autosampler. Inertsil ODS-3V,
250 mm  4.6 mm, 5 lm particle size was used for chromato-
graphic separation. Mobile phase-A as 20 mM ammonium for-
mate (pH 5.0 with formic acid) and mobile phase-B as
acetonitrile was used. The flow rate was maintained at
1.0 mL min1 and the injection volume is 10 lL. The gradient
program was 0.01 min – 30% B, 5.0 min – 30% B, 15.0 min
– 35% B, 30.0 min – 45% B, 45.0 min – 55% B, 54.0 min
– 65.0% B, 55.0 min – 30.0% B and 60.0 min – 30.0% B.
The column temperature was 30 C.
2.5. Preparative HPLC
A Shimadzu LC-8A Preparative LC equipped with SPD-10
AVP, UV–VIS detector (Shimadzu Corporation, Analyticalr the determination of potential impurities in dabigatran etexilate in bulk drug
0.1016/j.arabjc.2015.09.006
Figure 3 Typical chromatograms of forced degradation of
dabigatran etexilate at control condition (a) acid hydrolysis, (b)
base hydrolysis, (c) peroxide stress, and (d) humidity stress.
6 J. Nagadeep et al.Instruments Division, Kyoto, Japan) was used. ACE C18
(250 mm  21.2 mm, particle size 10 lm) columns were
employed for separation and isolation of impurity using
ammonium formate (20 mM) as mobile phase-A and ACN
as mobile phase-B with varying compositions and flow rate
of 15–20 mL min1 and detection was carried out at 255 nm.
2.6. NMR spectroscopy
1H and 13C NMR spectra were acquired with AVANCE
(Bruker, Switzerland) 300 and 400 MHz spectrometers at room
temperature, 22 C using DMSO-d6 as solvent and tetramethyl-
silane (TMS) as internal standard. The data acquisition and
processing was carried out by XWIN-NMR software.
2.7. FT-IR spectroscopy
The FT-IR spectra were recorded as KBr pellets using Perki-
nElmer Spectrum-2 FT-IR Spectrometer (PerkinElmer Life
and Analytical Sciences, Shelton, CT, USA).
2.8. Differential scanning calorimeter (DSC)
The DSC Q200 (TA Instruments, Waters LLC) was used for
melting point determination.
2.9. Preparation of standard solutions
Working solutions containing 1000 lg mL1 DAB and
100 lg mL1 process related substance stocks were prepared
for the determination of related substances. Mixed and
individual stock solutions (100 lg mL1) of the impurities
(denoted as impurity-1 to impurity-15) were diluted to get a
concentration about 1.5 lg mL1 in diluent, which is in the
ratio of 70:30 (mobile phase-A:acetonitrile). The specification
limit considered for validation studies was 0.15% for each
impurity. Pradaxa (150 mg) capsule powder solution equiva-
lent to 1000 lg mL1 of the drug was prepared by dissolving
in the diluent and was filtered through a 0.45 lm nylon
membrane filter. The resulting solution was analyzed by HPLC
for the estimation of related substances.Figure 4 Typical chromatograms of (a) water stress of dabiga-
tran etexilate, (b) rigorous water stress of dabigatran etexilate, (c)
rigorous water hydrolysis followed by acid hydrolysis for 5 min of
dabigatran etexilate, and (d) rigorous acid hydrolysis of dabiga-
tran etexilate.3. Results and discussions
3.1. Synthetic process and identification of impurities
Method development was initiated by using crude samples at
various stages of synthetic process. A brief synthetic scheme
along with origination of by-products during the synthesis is
detailed in Fig. 1, where condensation of key starting materials
compound_1 and compound_2 gives a salt form of com-
pound_3, which is subsequently reacted to ethanolic
hydrochloric acid, ethanol and base to give the salt of ethyl
3-{[(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-
benzimidazol-5-yl)carbonyl](pyridin-2-yl)amino}propanoate
(compound_4). The reaction between compound_4 and
n-hexyl chloroformate, in the presence of potassium carbonate
and solvent gives dabigatran etexilate, finally treating
dabigatran etexilate with methane sulfonic acid in the presence
of solvent to give dabigatran etexilate mesylate salt. ThePlease cite this article in press as: Nagadeep, J. et al., Gradient RP-HPLC method f
and capsule formulations. Arabian Journal of Chemistry (2015), http://dx.doi.org/1mesylate salt (1:1) of dabigatran etexilate is known to be ther-
apeutically useful and is commercially marketed.
As a common practice, efforts should be made to identify
and characterize all unknown impurities in the drug substance
due to the ever increasing demand from regulatory agencies to
manufacture high purity drug substances. Impurity profiling of
drugs is the most important issue in modern pharmaceutical
analysis (Rao and Nagaraju, 2003; Go¨ro¨g, 2000; Ahuja,
1998) for developing process technology to manufacture high
purity drug substance. Hence, the method should be capable
of separating all potential related impurities, including starting
materials, by-products and degradants.
3.2. Optimization of chromatographic conditions
Drug impurity profiling, i.e., identification, structure elucida-
tion and quantitative determination of impurities and degrada-
tion products in bulk drug materials and pharmaceutical
formulations is one of the most important fields of activities
in modern pharmaceutical analysis (Bartos and Gorog,
2008). The main objective of this chromatographic method isor the determination of potential impurities in dabigatran etexilate in bulk drug
0.1016/j.arabjc.2015.09.006
Gradient RP-HPLC method for the determination of potential impurities 7to get the separation of DAB from all the process related
impurities, by-products and degradants. The knowledge of
drug properties such as logP and pKa was important, as most
of the pH-related changes in retention occur at pH values
within 1.5 units of the pKa value and logP gives an indication
about hydrophobicity or polarity nature of the molecule. The
selectivity of a separation also depends upon the chemistry of
the analyte i.e. the impurity-4 was depyridynyl form of
impurity-3 and impurity-11 and 12 were chain isomers of hexyl
group present on impurity-10 and impurity-13 and impurity-14
were differed by one methyl group. The main purpose of the
method development was to optimize selectivity of these criti-
cal closely eluting pair of compounds by altering mobile and
stationary phases.Figure 5 ESI-MS/MS fragmentation patterns for
Please cite this article in press as: Nagadeep, J. et al., Gradient RP-HPLC method fo
and capsule formulations. Arabian Journal of Chemistry (2015), http://dx.doi.org/1The blend containing 1000 lg mL1 of DAB and
1.5 lg mL1 of each impurity was prepared and used for
method optimization. To start the method optimization the
effect of pH (from 4.0 to 6.0) of ammonium formate buffer
was studied to understand the elution and separation of impu-
rities. To improve peak shapes 0.1%TEA was added as an
additive to the buffer. Preliminary experiments on method
development were carried out on Inertsil ODS 3V column
using pH 5.5–20 mM ammonium formate with 0.1% of tri-
ethylamine:ACN (60:40) (v/v) in isocratic mode. Six impurities
were merged and the same kind of separation was observed by
changing organic modifier as methanol. It was found that gra-
dient elution resulted better separation than isocratic mode of
elution on this column with acetonitrile as organic modifier butdabigatran etexilate and unknown-1 impurity.
r the determination of potential impurities in dabigatran etexilate in bulk drug
0.1016/j.arabjc.2015.09.006
8 J. Nagadeep et al.only the critical pair’s viz. impurity-11 and impurity-12,
impurity-13 and impurity-14 separation was not observed.
Attempts were made with gradient elution to separate the
critical pairs changing different column chemistries but no
selectivity was observed. The best results were obtained using
the chromatographic conditions given in Section 2.3 and the
typical chromatogram is shown in Fig. 2(a). The method
development trials are shown in Table 2.
The affinities of all impurities toward different commer-
cially available columns were also evaluated to get the best res-
olution between critical pair of impurities. Inertsil ODS 3V
column at pH 5.0 was selected to get the good resolution
between the critical pairs, which was due to its high surface
area, more hydrophobicity, and high reproducibility compared
with other commercially available columns. In this optimized
method all the peaks were symmetrical and show the tailing
factor 61.3 and the resolution P2.0 from blend chro-
matogram of system suitability. System suitability parameters
are described in Table 1.Figure 6 ESI-MS/MS fragmentation pattern
Please cite this article in press as: Nagadeep, J. et al., Gradient RP-HPLC method f
and capsule formulations. Arabian Journal of Chemistry (2015), http://dx.doi.org/13.3. Analysis of bulk drugs stability samples
During the analysis of active pharma ingredient (API) stability
sample, three impurities were observed, of which one was imp-
8 and other two were unknown. Unknown were eluted around
retention time 43.3 min (unknown-1) and 24.4 min (unknown-
2) (Fig. 2(b)). However, they did not match with any of the
process related substances by comparing retention times. The
compounds imp-8, unknown-1(imp-15) and unknown-2 were
present in 0.19%, 0.26% and 0.09% respectively and remain-
ing impurities were not detected. Attempts were made to eval-
uate these unknown impurities in stability sample using LC-
MS/MS analysis using the conditions given in Section 2.5.
The obtained fragmentation pattern for unknown-1 and
unknown-2 was comparable and structures were derived with
the help of known DAB and impurity-8 mass spectrums inter-
pretation. Two unknown impurities comparison with DAB
and impurity-8 detailed mass fragmentation shown in
Figs. 5 and 6.s for Impurity-8 and unknown-2 impurity.
or the determination of potential impurities in dabigatran etexilate in bulk drug
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Gradient RP-HPLC method for the determination of potential impurities 93.4. Degradation studies
Degradation study gives information about origin of
degradant impurities and also useful to check the stability-
indicating power of developed method. The forced degrada-
tion condition was attempted to get degradation not less than
10% (in order to get a mass balance between purity and assay).
Solution state forced degradation of DAB was carried out by
treating the 1.0 mg/ml solutions with 0.1 M HCl for 5 min at
75 C, 0.25 M NaOH for 30 min at 75 C and 3% H2O2 for
1 h at room temperature. Solid state forced degradation (ther-
mal, photolytic and humidity) of the drug was conducted by
exposing DAB to (1) heat at 105 C for 120 h, (2) white fluo-
rescent light of 1.2  106 lux followed by UV light of
200 W h/m2 and (3) 90% R.H. at 25 C for 120 h. All these
solutions are analyzed by the developed method conditions
mentioned in Sections 2.3 and 2.4. One degradant which was
observed in bulk drug stability sample i.e. unknown-1 was
detected at 0.6% level in humidity condition and no forcedFigure 7 Proposed degradation pathway fo
Please cite this article in press as: Nagadeep, J. et al., Gradient RP-HPLC method fo
and capsule formulations. Arabian Journal of Chemistry (2015), http://dx.doi.org/1degradation was observed in heat and exposure with light.
Peak purity test was carried out on the stressed samples of
DAB by using DAD detector. Assay studies were carried out
for stress samples against qualified reference standard
and the mass balance (% assay +% degradation) is
calculated (Table 4). Stress chromatograms are illustrated in
Fig. 3(a)–(d).
3.5. Enrichment of unknown-1 and unknown-2 impurities
Degradation in controlled conditions (i.e. 610%) gives a con-
clusion that unknown-1 was increasing in humidity stress.
Based on mass spectral data and degradation studies attempts
were made to enrich the impurity using forced degradation
with water. The unknown-1 impurity increased about 9% in
water stress at 75 C for 30 min and about 88% when
extending the stress time to 12 h (Fig. 4(a) and (b)). Intentional
addition of 0.1 N HCl to 88% degraded water stress sample
and holding for 5 min give a rise of unknown-2 impurityr unknown-1 and unknown-2 impurity.
r the determination of potential impurities in dabigatran etexilate in bulk drug
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Figure 8 FT-IR spectrums of (a) dabigatran etexilate and (b)
unknown-1 (Impurity-15).
10 J. Nagadeep et al.(Fig. 4(c)). The unknown-2 impurity formation was also
observed in intentional rigorous stress of DAB using 1 M HCl
(Fig 4(d)). The stress solutions were injected into LC-MS/MS
analysis to generate unknown impurities (unknown-1 and 2)
mass spectral data and these were matching with unknown
impurity mass spectrums of bulk drug stability sample.
3.6. Isolation of unknown-1 impurity using preparative LC
In order to isolate the unknown-1 impurity from water stress
of DAB, the isolation conditions for preparative LC used were
as mentioned in Section 2.5. Approximately 0.2 g of sample
was injected on to column every time and this loading was con-
tinued until the sufficient amount of unknown-1 was isolated
(20 injections). The fractions containing >95% of
unknown-1 were collected, concentrated using rotary evapora-
tor at 30 C under vacuum and finally lyophilized to obtain
solid product.
3.7. Degradation pathway for unknown-1 and unknown-2
During the experiment-enrichment of unknown impurities, it
was observed that intentional addition of acid to water stress
of dabigatran etexilate gives rise of unknown-2 impurity
(Fig. 4(c)). Based on stress study and mass spectrum fragmen-
tation data the degradation pathway for unknown-1 and
unknown-2 is proposed as shown in Fig. 7.
3.8. Structural elucidation of unknown-1
In the positive mode ESI-MS analysis of the unknown-1 exhib-
ited a protonated molecular ion peak m/z 629. The difference
of mass between impurity and DAB is 1 amu, indicating dele-
tion and addition on DAB. During degradation studies this
was major impurity observed in water hydrolysis of DAB.
The imine group (AC‚NH) on DAB hydrolysis to carbonyl
(AC‚O) leads to increase of 1 amu mass for impurity. This
was evidenced by major product ions observed from ESI-
MS/MS of DAB m/z 526,500, 434, 350, 332 and 306 and of
unknown-1(impurity-15) were at m/z 527,435, 351,333 and
308 (Fig. 5). The 1H, 13C NMR and FT-IR spectral data of
DAB and unknown-1 impurity are given in Table 3 and
Fig. 8 respectively. 1H NMR spectral data of unknown-1
showed chemical shift similarity with DAB in all positions
except the signals corresponding to ANH2 in DAB was absent
in impurity. From 13C spectral data the change in chemical
shift values at eighth position of carbon gives an evidence of
hydrolysis of imine group (AC‚NH) on DAB to a carbonyl
(AC‚O). From this spectral information the structure was
confirmed as ethyl 3-{[(2-{[(4-{[({hexyloxy}carbonyl)amino]car
bonyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)
carbonyl](pyridin-2-yl)amino}propanoate. Determined the
melting point by DSC for unknown-1 and DAB, the results
are 185 C and 178 C respectively.
3.9. Structural elucidation of unknown-2
The impurity unknown-2 exhibited a protonated molecular ion
peak at m/z 601 in positive ion ESI-MS analysis; the difference
of mass between DAB and impurity was 27 amu and differencePlease cite this article in press as: Nagadeep, J. et al., Gradient RP-HPLC method f
and capsule formulations. Arabian Journal of Chemistry (2015), http://dx.doi.org/1of mass between unknown-1 and this impurity was 28 amu,
indicating absence of ACH2CH3 i.e. ester hydrolysis of corre-
sponding unknown-1 (Fig. 7). Hydrolysis (ester hydrolysis) of
DAB (m/z 628) mainly results in the formation of a compound
impurity-8 (m/z 600). Similarly the hydrolysis of unknown-1
(m/z 629) results in a formation of compound unknown-2 hav-
ing m/z 601. This was evidenced by comparing ESI-MS/MS
major product ions of impurity-8 m/z 452, 434 and 332 and
of unknown-2 were at m/z 453, 435 and 333 (Fig. 6). From
this mass spectrum fragmentation pattern comparison, the
Unknown-2 structure was predicted as 3-{[(2-{[(4-{[({hexy-
loxy}carbonyl)amino]carbonyl}phenyl)amino]methyl}-1-met-
hyl-1H-benzimidazo1-5-yl) carbonyl] (pyridin-2-yl)amino}
propanoic acid.
3.10. Method validation
3.10.1. Precision
The repeatability of the method was examined by sixfold anal-
ysis of 1000 lg mL1 of DAB by spiking with impurities 1 to
15 at the level of 0.15% i.e. 1.5 lg mL1. The %RSD for the
area of impurities was well within 2.6%. Interday precision
was evaluated using different analyst and a different instru-
ment in the same laboratory, and the %RSD for the area of
impurity-1 to impurity-15 was well within 2.4%, confirming
good precision of the method. The %RSD values are pre-
sented in Table 5.
3.10.2. Accuracy
Accuracy expresses the closeness of the agreement between the
true value and the value obtained. Accuracy of the method was
evaluated ranging from LOQ to 150% of target impurity con-
centration 0.15 lg mL1 (in triplicate) in bulk drug sample and
in dosage form. The percentage recovery of impurities was var-
ied from 95.8% to 99.2%. The LC chromatogram of spiked
sample at 0.15% level of all fifteen impurities in DAB sample
is shown in Fig. 2(a). The % recovery values of impurities are
presented in Table 6.or the determination of potential impurities in dabigatran etexilate in bulk drug
0.1016/j.arabjc.2015.09.006
Table 5 Validation summary for DAB and its impurities.
Parameter Imp-1 Imp-2 Imp-3 Imp-4 Imp-5 Imp-6 Imp-7 Imp-8 Imp-9 Imp-10 Imp-11 Imp-12 DAB Imp-13 Imp-14 Imp-15
Regression equation
Slope (b) 34,402 8239 29,611 16,697 32,897 38,660 8359 26,135 39,782 23,560 19,895 26,256 24,715 20,297 23,886 37,727
Intercept (a) 1067 322 58 147 30 83 148 197 195 625 287 393 82 169 89 490
R value 0.9996 0.9996 0.9999 0.9998 0.9999 0.9999 0.9998 0.9999 0.9997 0.9998 0.9999 0.9999 0.9999 0.9998 0.9997 0.9999
R2 value 0.9993 0.9992 0.9999 0.9997 0.9999 0.9999 0.9996 0.9999 0.9995 0.9996 0.9999 0.9998 0.9997 0.9996 0.9993 0.9998
LOD (lg/mL) 0.11 0.122 0.047 0.072 0.039 0.047 0.084 0.033 0.094 0.079 0.043 0.056 0.07 0.078 0.107 0.054
LOQ (lg/mL) 0.334 0.37 0.143 0.218 0.119 0.143 0.253 0.1 0.283 0.24 0.131 0.169 0.211 0.237 0.324 0.164
Precision at LOQ n= 6
(%RSD)
5.1 6.6 3.4 7.2 4.2 5.3 7.9 3.9 3.2 4.4 8.3 4.6 4.4 3.4 4.2 4.1
Precision n= 6 (%RSD) 1.12 1.92 0.65 2.6 0.92 0.53 2.2 1.21 1.36 0.52 2.1 0.63 0.75 0.81 1.21 1.16
Intermediate n= 6
precision (%RSD)
0.63 1.6 1.03 1.8 1.24 0.63 2.4 0.65 0.89 0.65 2.6 0.76 0.52 0.93 0.96 0.78
Table 6 Evaluation of accuracy.
Amount
spikeda
%Recoveryb
Imp-1 Imp-2 Imp-3 Imp-4 Imp-5 Imp-6 Imp-7 Imp-8 Imp-9 Imp-10 Imp-11 Imp-12 DAB Imp-13 Imp-14 Imp-15
LOQ 95.8 ± 2.8 94.5 ± 4.4 95.6 ± 3.2 96.8 ± 4.2 97.3 ± 2.2 96.4 ± 2.6 98.2 ± 4.6 97.4 ± 2.1 94.5 ± 2.5 96.5 ± 1.2 95.8 ± 3.4 97.8 ± 2.1 96.3 ± 2.4 97.4 ± 2.5 98.2 ± 2.8 96.4 ± 2.1
50% 97.3 ± 1.2 98.2 ± 0.6 97.2 ± 0.8 98.3 ± 1.1 96.8 ± 1.8 98.6 ± 1.4 97.2 ± 2.1 96.4 ± 1.1 97.1 ± 1.3 96.5 ± 0.6 98.2 ± 0.9 97.1 ± 0.6 98.2 ± 0.7 97.3 ± 1.1 97.4 ± 0.9 97.8 ± 1.1
100% 98.1 ± 0.6 96.4 ± 1.2 98.3 ± 0.9 95.2 ± 1.2 97.2 ± 0.9 94.5 ± 1.5 96.3 ± 1.1 98.2 ± 0.8 97.9 ± 0.6 96.2 ± 1.0 95.8 ± 0.6 98.2 ± 0.4 97.3 ± 0.7 98.4 ± 0.2 99.1 ± 0.3 98.9 ± 0.6
150% 97.8 ± 0.9 98.2 ± 0.8 98.4 ± 1.1 97.5 ± 0.6 98.1 ± 0.4 98.9 ± 1.1 97.9 ± 1.6 99.2 ± 0.4 98.6 ± 1.1 99.1 ± 0.9 97.1 ± 0.8 98.5 ± 1.1 98.6 ± 0.9 95.4 ± 1.1 97.3 ± 0.3 99.0 ± 0.8
a Amount of fifteen impurities spiked with respect to 0.15% specification level individually to 1.0 mg/ml of dabigatran etexilate.
b Mean %RSD for three determinations.
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The LOD and LOQ were determined for DAB and each of the
impurities based on the standard deviation (SD) of the
response and slope (S) of the regression line as per ICH guide-
line according to the formulas given below:
LOD ¼ 3:3 SD=S; LOQ ¼ 10 SD=S
The residual sum of squares obtained from linearity regression
data was used as SD.
The concentrations of LODs and LOQs for DAB and its
impurities were found to be in the range of 0.033–
0.122 lg mL1 and 0.1–0.370 lg mL1 respectively. The con-
centrations of LOQs were verified for precision by the analysis
of solutions having DAB and its impurities at these levels in six
replicates and are found below 10% RSD (Table 5).
3.10.4. Linearity
Linearity solutions were prepared from impurity stock solu-
tion at six different concentration levels ranging from LOQ
to 150% of target concentration i.e. 2.25 lg mL1. The cali-
bration curve was drawn by plotting impurity area versus the
concentration .The correlation coefficient obtained was greater
than 0.999 for all the impurities (Table 5).
3.10.5. Solution stability and mobile phase stability
The variability in the estimation of DAB impurities was within
±10% during solution stability and mobile phase experiments
when performed using the method. The results from solution
stability and mobile phase stability experiments confirmed that
standard solutions, sample solutions and the mobile phase
were stable up to 48 h for related substances analysis.
3.10.6. Robustness
In all the deliberate varied chromatographic conditions (flow
rate, column temperature and composition of organic solvent),
all analytes were adequately resolved and elution order
remains unchanged. The effect of pH on resolution of impuri-
ties was also studied by varying ±0.2 pH units (at 4.8 and 5.2
buffer pH instead of 5.0). The resolution between critical pairs,
i.e. for impurity-10, impurity-11 and impurity-12 and for
impurity-13 and impurity-14 was greater than 2.0 and tailing
factor for DAB and its impurities was less than 1.2. The vari-
ability in the estimation of impurities was within ±10%. There
is no significant change observed by deliberate changes, which
confirms the robustness of the method.
4. Conclusion
A gradient RP-HPLC method was developed and validated for
quantitative determination of impurities of dabigatran etexi-
late drug substance. The method has higher sensitivity toward
the determination of impurities and is found to be specific, sen-
sitive, precise, linear, accurate and robust. Two unknown
impurities were identified by LC-MS/MS. The isolated
unknown-1 impurity was characterized using 1H, 13C, FT-IR
and mass spectrometry. The unknown-2 was found as sec-
ondary degradant; hence, attempts were not made to isolate
this impurity but its degradation pathway and structure were
proposed based on mass spectral data. The developed method
is stability-indicating and can be used for assessing the stabilityPlease cite this article in press as: Nagadeep, J. et al., Gradient RP-HPLC method f
and capsule formulations. Arabian Journal of Chemistry (2015), http://dx.doi.org/1of bulk samples, dosage forms and also for monitoring the syn-
thetic procedures of dabigatran etexilate.
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